
What DOJ’s October 2026 Corporate Fraud Priorities Mean for Life Sciences Companies
On October 1, 2026, the U.S. Department of Justice’s (“DOJ”) National Fraud Enforcement Division issued Directive 26-12, Corporate Enforcement in the Fight Against Fraud. The directive prioritizes healthcare, government, revenue, and trade fraud. Its healthcare focus expressly includes controlled-substance distribution and violations of the Federal Food, Drug, and Cosmetic Act. For pharmaceutical, biotechnology, medical device, and healthcare companies, Kendall PC’s practical takeaway is clear: leadership should examine how compliance concerns move from identification to investigation, corrective action, and verified resolution.
What the Directive Changes
The directive guides Fraud Division enforcement decisions within DOJ’s existing corporate prosecution framework. It directs prosecutors to give substantial weight to management knowledge or involvement, concealment, threats to safety or security, and harm to government programs. Specified scale factors include conduct lasting at least three years, affecting at least three federal districts, or causing financial harm to at least 25 victims or losses of at least $25 million. These considerations are nonexclusive, not minimum requirements for prosecution.
The Division’s Corporate Enforcement Section will coordinate corporate matters and evaluate compliance with criminal resolutions. DOJ also highlights data analytics and directs development of whistleblower incentives; the memorandum does not itself establish a completed new incentive program.
Why This Matters for Life Sciences Companies
In our view, the directive warrants a coordinated review of regulatory, commercial, financial, and compliance controls. Companies should consider where product information, promotional activity, pricing arrangements, reimbursement support, government submissions, and supply-chain decisions intersect. A useful review begins with a practical question: can the company reconstruct why a consequential business decision was made, who approved it, what conditions applied, and whether those conditions were followed?
For example, a new pricing arrangement may require input from commercial leadership, finance, contracting, legal, compliance, and government pricing personnel. Our recommendation is to establish that review before implementation, document the decision, and revisit it when the arrangement changes. Informal assumptions about another department’s approval can leave important issues unresolved. Note that these are recommended areas for assessment, not a prediction that every regulatory deficiency or commercial disagreement will become a criminal fraud case. Liability depends on the applicable law and facts.
Management Oversight Must Produce Action
DOJ’s broader corporate prosecution framework considers the pervasiveness of misconduct, the involvement of management, the effectiveness of compliance programs, and remediation. Companies should therefore test whether their governance process produces timely decisions when concerns arise.
Kendall PC recommends assigning a responsible owner, a deadline, and a verification step to significant corrective actions. Leadership should receive enough information to assess unresolved risks and determine whether an activity should pause while the facts are investigated. Written legal or compliance recommendations should also be translated into operational instructions. If approval depends on safeguards, employees implementing the activity need to understand those safeguards, and the company should confirm that they are working.
Internal Reporting and Investigation Readiness
We recommend evaluating whether employees can report concerns through accessible channels, whether reports reach an appropriate reviewer, and whether potential conflicts are addressed when management is implicated. When a credible allegation arises, companies should promptly preserve relevant records, assess ongoing exposure, and determine the appropriate investigation scope with counsel. Interviews, transaction data, approvals, and contemporaneous communications may each help distinguish an isolated mistake from a broader control failure.
Counsel should assess privilege at the outset. Copying an attorney or labeling a document “privileged” does not, by itself, establish protection. Disclosure decisions likewise deserve early legal assessment. DOJ’s corporate prosecution framework recognizes voluntary disclosure, cooperation, and remediation, but the availability of credit depends on the governing policy and circumstances. Companies should establish a process for making those decisions promptly while preserving a careful assessment of the facts.
Practical Steps for Companies
Kendall PC recommends that companies:
- Refresh risk assessments around government funds, product integrity, and material regulatory representations.
- Clarify approval authority and require renewed review when business practices change.
- Test reporting, escalation, and investigation procedures using realistic scenarios.
- Track corrective actions through completion and verify their effectiveness.
- Review whether incentives and disciplinary practices support consistent compliance expectations.
A useful compliance program gives leadership reliable information and enables employees to act on it. Companies should use this announcement to assess whether their policies, controls, and management practices accomplish that result.
Kendall PC assists pharmaceutical, biotechnology, medical device, and healthcare companies with legal and regulatory counseling, compliance programs, internal investigations, and practical risk management.
This article provides general information and does not constitute legal advice.
